GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Neurocrine Biosciences NBIX · USD

Health Care · US listing · 🇺🇸 United States

Compare

168.86

+2.57%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Analyst ratings

37 analysts, 1 Nov 2026. The analysts' own views, not ours.

  • 15Strong buy
  • 17Buy
  • 5Hold
  • 0Sell
  • 0Strong sell

Price targets

Brokers' own targets, 1 Nov 2026. Not our view.

Last close 168.86Average target 200.84

Low
160.00
Average
200.84
Median
204.00
High
230.00

Forecasts

Analyst averages for the fiscal years ahead

FY2026FY2027FY2028FY2029FY2030
Revenue$3.90bn$4.51bn$5.03bn$5.25bn$5.62bn
Revenue, highest$3.92bn$5.04bn$5.32bn$5.60bn$6.00bn
Revenue, lowest$3.87bn$4.11bn$4.71bn$5.00bn$5.36bn
Earnings per share7.139.5712.1512.7413.88
Earnings per share, highest7.4913.1216.9113.8615.10
Earnings per share, lowest6.436.849.2611.9613.03
Analysts2019201010

Earnings against forecasts

Earnings per share by fiscal quarter

Q3 2026Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024
Forecast1.911.651.181.921.620.990.561.59
Reported3.291.391.911.482.041.060.081.00
Difference+72.3%-15.8%+62.3%-22.9%+26.1%+7.0%-85.6%-37.2%

Rating changes

Latest broker notes

  • Morgan StanleyEqual Weight
  • WedbushOutperform
  • Truist SecuritiesBuy
  • Canaccord GenuityBuy
  • TD CowenBuy
  • StifelBuy
  • RBC CapitalOutperform
  • Piper SandlerOverweight
  • NeedhamBuy
  • Morgan StanleyEqual Weight
  • GuggenheimBuy
  • CitigroupBuy

Quality and value scores

Models run by our data supplier, not our view and not investment advice

Model

Quality score

6 / 10

Revenue growth 64.5% a year over 10 years. Return on equity 14.7%.

Model fair value

206.34

From earnings 206.34, from revenue 178.29.

Piotroski score

3 / 9

A nine-point test of financial strength, for 31 Dec 2025.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.